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Summary To document the rate and cost of antibiotic prescribing for patients
diagnosed only with influenza during US ambulatory care visits. Federal survey data
for 1997–2001 were used to estimate outpatient trends for all patients and healthy
people age 5–49 years. Cost estimates were based on Medicare payments and Red
Book average wholesale prices in 2003. Antibiotic prescribing for influenza is
widespread; 38% of visits led to an antibiotic prescription of which one-third were for
broad spectrum antibiotics. Inappropriate antibiotics cost $18.5 million annually and
may contribute to resistance. Increased vaccination rates and viral testing could
reduce these trends.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
A series of large-scale studies has demonstrated
that antibiotics are commonly prescribed for colds,
upper respiratory tract infections (URIs), and
bronchitis among both children and adults. Such
usage constitutes a large percentage of the total
antibiotic prescribing which occurs in ambulatory
practice, and is generally reflective of inappropri-
ate treatment for infections of primarily viral
etiology.1–3 This inappropriate use of antibiotics
has contributed to the growing public health
problem of antibiotic resistance among pathogenic
bacteria.4,5 In addition, widespread antibiotic
overuse has been shown to carry with it substantial
cost implications.6,7 Recent reports indicate that
rates of inappropriate antibiotic prescribing for
colds, URIs and bronchitis peaked in the mid-1990s
and may be decreasing modestly, although they
remain at unacceptably high levels.8–12
Most prior analyses of inappropriate antibiotic
use in ambulatory care have examined diagnostic
codes characterized by clinical terminology sugges-
tive of a viral etiology. No studies, to our knowl-
edge, have examined rates of antibiotic prescribing
in ambulatory care for cases in which the sole
recorded diagnosis is influenza. Influenza, a viral
respiratory illness, is known to present with a
clinical picture characterized by febrile respiratory
illness in which symptoms are often severe and of a
systemic nature.13 Notwithstanding the severity of
influenza, the inherent viral etiology of the
diagnosis by definition precludes appropriate use
of antibiotics in those cases in which it is the sole
diagnosis. We therefore undertook this study
specifically to ascertain the rate and associated
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cost of antibiotic prescribing in ambulatory prac-
tice for patients diagnosed only with influenza. By
restricting cases to those for which influenza is the
sole recorded diagnosis, judgment as to the
appropriateness of antibiotic prescribing is made
even less subjective compared to prior analytic
approaches.
We focus our analysis on patients between the
ages of 5 years and 49 years for three reasons. First,
most prior studies of disease burden attributable to
influenza have historically focused on groups at
high risk of complications from influenza (such as
the elderly and young children) while compara-
tively few studies have looked at influenza-asso-
ciated disease burden within this age range; thus a
gap in the epidemiologic literature exists for this
population subgroup. Second, new advances in
influenza prevention target this age range.14 Lastly,
within the specific subgroup of 5–49 year olds,
there is a diminished likelihood that clinicians’
concerns about possible complications (such as
bacterial superinfections) would influence thera-
peutic decision-making. For all of these reasons,
our research question addresses a novel and
unaddressed area that is relevant within the
current context of influenza prevention, diagnosis
and treatment.
Methods
The National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory
Medical Care Survey (NHAMCS) data were used for
this analysis. These ambulatory medical care
datasets are provided by the National Center for
Health Statistics (NCHS), a subdivision of the US
Centers for Disease Control and Prevention. The
datasets are free for public use and can be
downloaded from the NCHS website (http://www.
cdc.gov/nchs/about/major/ahcd/ahcd1.htm).
Both the NAMCS and NHAMCS are national visit-
based surveys designed to collect information
annually about the provision and utilization of
ambulatory medical care services. The NAMCS is
based on visits to nonfederally employed office-
based physicians. The NHAMCS is collected on visits
to the emergency and outpatient departments of
noninstitutional general and short-stay hospitals,
exclusive of federal, military, and Veterans Admin-
istration hospitals, located in the 50 states and the
District of Columbia.
The NAMCS survey is completed by physicians and
their staff, whereas the NHAMCS is completed by
hospital staff. The same data form is used to collect
information in the office and outpatient depart-
ment settings. A different form is used to capture
information in the emergency department. Both
forms contain information about the visit including
demographic data, up to three diagnoses and up to
six medications ordered, supplied, administered or
continued. Free text diagnoses and medications are
coded by NCHS to International Classification of
Disease ( ICD-9-CM) codes and NCHS drug codes,
respectively.
The NAMCS uses a three-stage probability sample
design. The three stages include probability sam-
ples of geographically defined areas (primary
sampling units or PSUs), physician practices within
these areas and patient visits within practices. The
NHAMCS uses a four-stage probability design with
samples of geographically defined areas, hospitals
within these areas, clinics within hospitals, and
patient visits within clinics.
National estimates were produced by weighting
the NAMCS and NHAMCS samples using the patient
visit weights provided. Estimates reported in this
analysis are based on sample cases of 30 or more
and have relative standard errors (RSE) less than
30%. Standard errors were used to calculate the
95% confidence intervals (CI) around the estimates.
The SURVEYMEANS procedure in SAS version 8.2
(Cary, NC) was used to calculate estimates of
population totals and means with estimates of
variances and confidence limits.15 When appropri-
ate, the DOMAIN statement was used in the
SURVEYMEANS procedure to perform statistically
valid subpopulation analyses.
The NAMCS and NHAMCS data from 1997 to 2001
were merged with each other for this analysis.
Combining the datasets creates a larger sample and
allows for analyses across multiple settings. These 5
years of data could be combined because the
questions of interest were asked consistently over
the years.16 SAS version 8.2 software was used for
all statistical analyses. Microsoft Excel was used to
calculate population-based visit rates using post-
censal estimates of noninstutionalized civilian
population provided by the US Bureau of Census
(http://eire.census.gov/popest/data/national/as-
ro detail.php).
Inclusion criteria
Visits by individuals age 5–49 years with an
influenza diagnosis were identified in both the
NAMCS and NHAMCS data. Up to three diagnoses
may be recorded for each visit. Diagnoses written
as free text are coded by NCHS staff as ICD-9-CM
ARTICLE IN PRESS
1094 G. Ciesla et al.
codes. The following ICD-9-CM codes were used to
identify influenza for this analysis:
* 487.0 Influenza with pneumonia
* 487.1 Influenza with other respiratory manifes-
tations
* 487.8 Influenza with other manifestations
To reduce the number of individuals with
comorbid conditions, the analysis cohort was
limited to subjects who had only a primary
diagnosis of influenza and no secondary diagnoses.
Identification and classification of antibiotics
Prescribed drugs are recorded in the NAMCS and
NHAMCS by trade name, generic name, desired
therapeutic effect or by ingredient names for
combination products. These free text responses
are recoded using unique NCHS-assigned medica-
tion codes. Medications were queried using the
Ambulatory Care Drug Database System (http://
www2.cdc.gov/drugs) provided by NCHS to obtain
drug name, generic name and therapeutic class.
Medications assigned to the following NCHS-as-
signed therapeutic classes were identified as anti-
biotics: penicillins (346); cephalosporins (347);
erythromycins, lincosamides and macrolides (348);
polymyxins (349); tetracyclines (350); chloramphe-
nicol and derivatives (351); aminoglycosides (352);
sulfonamides and trimethoprim (353); and quino-
lones and derivatives (357). Antibiotics were
further classified as broad- or narrow-spectrum
based on methods used in a previous study12 and
expert opinion (Table 1).
Visit costs
Three current procedural terminology (CPT) codes
matching the expected level of care and reported
patient status (new or established) were selected
to represent the professional services likely ren-
dered at an influenza-related ambulatory care
visit. CPT 2003 Professional Edition was used to
define CPT codes (Table 2). The selected CPT codes
were assigned to each visit by care setting and
patient status. Patient status was not reported for
emergency department visits.
The Medicare national average allowance (NAA)
for each CPT code was calculated using the
National Fee Schedule Relative Value File
provided by the Centers for Medicare and Medicaid
Services (http://cms.hhs.gov/providers/pufdown-
load/rvudown.asp). The NAA is the average
Medicare payment calculated by summing the
relative value units (RVUs) for a specific procedure
and multiplying the sum by $36.7856, the 2003
Medicare conversion factor (CF). Geographic
practice cost indices (GPCI) are not needed
in the NAA calculation since the average GPCI is
1.0 (Table 2).
Drug costs
Since prescribed dosing and duration of therapy are
not available in the survey data, we used the
recommended doses listed in the Physicians’ Desk
References (PDR) Electronic Libraryt for each
antibiotic recorded.17 Duration of therapy ranged
from a single dose to 10 days. Antibiotics were then
queried in the Medical Economics RED BOOKt
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Table 1 Antibiotics classified as broad- or narrow-spectrum.
Broad-spectrum Narrow-spectrum
Amoxicillin-clavulanate potassium Amoxicillin
Azithromycin Ampicillin
Cefaclor Cefadroxil
Cefotaxime Cephalexin
Cefprozil Cephapirin
Ceftizoxime Cephradine
Ceftriaxone Cyclacillinn
Cefuroxime axetil Erythromycin
Ciprofloxacin Erythromycin ethylsuccinate
Clarithromycin Erythromycin-sulfisoxazole
Doxycycline Penicillinn
Levofloxacin Penicillin G
Loracarbef Penicillin V
Tetracycline Sulfamethoxazole/trimethoprim
nDiscontinued product or vague description provided in NCHS Ambulatory Care Drug Database System. Cost estimates for
penicillin V were used.
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database.18 This database provides information
about average wholesale prices (AWP) for drugs,
direct prices, federal upper limit prices and
complete package information including dosage
form, route of administration, strength and size.
AWPs obtained from RED BOOKt were used to
derive a cost for each antibiotic prescription,
expressed as 2003 US dollars. The April 2003
release of the RED BOOKt was used.
The recommended standard dose, duration of
therapy and average wholesale price were used to
calculate a drug cost for each antibiotic prescribed.
Individual drug costs were averaged by group to
create an unweighted mean cost for broad- and
narrow-spectrum antibiotics. The unweighted
mean cost was assigned to each visit based on the
group of antibiotics prescribed. Then the un-
weighted mean group costs were weighted to
produce national estimates of total antibiotic
costs. Drug costing assumes that recorded anti-
biotic prescriptions were filled.
Results
All ages
An estimated 14.4 million (95% CI:12.1–16.8)
ambulatory care visits in the US were made by
children and adults of all ages for a primary
diagnosis of influenza over a 5-year period, 1997–
2001. Seventy-five percent of these visits were for
a primary diagnosis of influenza with no secondary
diagnoses (Table 3). The cumulative visit rate to
physician offices, hospital outpatient departments
and hospital emergency departments was 7.9/1000
persons (95% CI:6.5/1000–9.4/1000). Annual visit
rates ranged from 5.2/1000 persons (95% CI:4.2/
1000–6.2/1000) to 12.7/1000 persons (95% CI:8.0/
1000–17.3/1000).
Ages 5–49 years
An estimated 8.3 million (95% CI:6.6–10.0) ambu-
latory care visits in the US were made by children
and adults age 5–49 years for a primary diagnosis of
influenza over a 5-year period, 1997–2001. Se-
venty-eight percent of these visits were for a
primary diagnosis of influenza with no secondary
diagnoses (Table 3). The visit rate for patients age
5–49 years over the 5-year period to physician
offices, hospital outpatient departments and hos-
pital emergency departments was 7.4/1000 persons
(95% CI: 5.6/1000–9.1/1000). Annual visit rates
ranged from 3.9/1000 persons (95% CI: 2.6/1000–
5.2/1000) to 12.8/1000 persons (95% CI: 6.5/1000–
19.2/1000). The average number of visits per year
was 1.3 million.
The cumulative visit rate for children age 5–17
years was higher than the visit rate for adults age
18–49 years: 8.5/1000 persons (95% CI: 5.6/1000–
11.3/1000) and 6.9/1000 persons (95% CI: 5.1/
1000–8.7/1000), respectively. The visit rate for
children age 5–17 years in the office-based physi-
cian setting was 7.5/1000 persons (95% CI: 5.3/
1000–9.7/1000) compared to 5.7/1000 persons
(95% CI: 4.1/1000–7.3/1000) for adults age 18–49
years (Table 4).
All subsequent analyses were performed on the
cohort of children and adults age 5–49 years with a
primary diagnosis of influenza and no secondary
diagnoses coded for the visit.
Females made 56.8% of all ambulatory care visits
for influenza during the 5-year period. The overall
visit rate for all females was 8.3/1000 (95% CI: 6.5/
1000–10.2/1000) compared to 6.4/1000 (95% CI:
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Table 2 CPT codes, descriptions and Medicare national average allowance (USD, 2003).
CPT code CPT description NAA (USD, 2003)
99202 Office or other outpatient visit for the evaluation and management of a new
patient. Usually the presenting problem(s) are of low to moderate severity.
Physicians typically spend 20min face-to-face with the patient and/or
family
$62.54
99213 Office or other outpatient visit for the evaluation and management of an
established patient. Usually, the presenting problem(s) are of low to
moderate severity. Physicians typically spend 15min face-to-face with the
patient and/or family.
$51.13
99283 Emergency department visit for the evaluation and management of a
patient. Usually, the presenting problem(s) are of moderate severity.
$60.33
Source: CPTcodes and descriptions were obtained from the CPT 2003 Professional Edition (American Medical Association, 2002).
NAAs were calculated from the Medicare National Fee Schedule.
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4.1/1000–8.7/1000) for males. Patients were pre-
dominantly white (84.3%) with a visit rate of 7.7/
1000 (95% CI: 5.8/1000–9.7/1000). Blacks made
13.8% (7.5/1000; 95% CI: 3.0/1000–12.0/1000) of
visits and other races made the remaining 1.9% of
visits. The three most common expected sources of
payment were private insurance, Medicaid and self-
pay. Over the 5-year period, private insurance
accounted for 63.5%, Medicaid 15.7% and self-pay
13.2% of the expected payment sources.
Data from three ambulatory care settings were
combined for this study: office-based physicians,
hospital outpatient departments and hospital
emergency departments. Visits to office-based
physicians accounted for 85% of all visits made by
this age cohort over the 5-year period. Nearly 11%
of visits were made to hospital emergency rooms
and the remaining 4.9% were made to hospital
outpatient departments. The clinic type is avail-
able for the 320 058 visits (95% CI: 188 499–451 617)
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Table 3 Frequency of influenza visits in the ambulatory care setting, 1997–2001.
Characteristic All ages Age 5–49 years
Estimate % of
visits
Visit rate
per
1000n
Estimate % of
visits
% of all
influenza visits
Visit rate
per
1000n
All visits with an
influenza dx
16 277 509 100.0 8.7 9 364 429 100.0 57.5 7.6
All visits with a 11 dx
of influenza
14 414 833 88.6 7.7 8 336 613 89.0 57.8 6.7
Other 21 dx(s) 3 675 323 25.5 2.0 1 761 235 21.1 47.9 1.4
No other 21 dx(s) 10 739 510 74.5 5.7 6 575 378 78.9 61.2 5.3
All visits with a 21 dx
of influenza
1 862 676 11.4 1.0 1 027 816 11.0 55.2 0.8
Source: CDC’s National Center for Health Statistics. Public use files (micro-data), National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey, 1997–2001.
nBased on US Bureau of the Census monthly postcensal estimates of the civilian noninstitutionalized population of the United
States as of July 1 each year.
Table 4 Estimated numbers of ambulatory care visits, distribution and visit rates in the US by children and adults
age 5–49 years with a sole diagnosis of influenza, 1997–2001.
Setting 5–17 years 18–49 years 5–49 years
Physician office
Number of visits 1 928 562 3 632 176 5 560 738
Percent distribution 88.0% 82.9% 84.6%
Visit rate per 1000n (95% CI) 7.5 (5.3, 9.7) 5.7 (4.1, 7.3) 6.2 (4.4, 8.1)
Hospital outpatient department
Number of visits 105 155 214 903 320 058
Percent distribution 4.8% 4.9% 4.9%
Visit rate per 1000n (95% CI) 0.4 (0.2, 0.6) 0.3 (0.2, 0.5) 0.4 (0.2, 0.5)
Hospital emergency department
Number of visits 158 547 536 035 694 582
Percent distribution 7.2% 12.2% 10.6%
Visit rate per 1000n (95% CI) 0.6 (0.4, 0.9) 0.8 (0.7, 1.0) 0.8 (0.6, 1.0)
Combined settings
Number of visits 2 192 264 4 383 114 6 575 378
Percent distribution 33.3% 66.7% 100.0%
Visit rate per 1000n 8.5 (5.6, 11.3) 6.9 (5.1, 8.7) 7.4 (5.6, 9.1)
Source: CDC’s National Center for Health Statistics. Public use files (micro-data), National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey, 1997–2001.
nBased on US Bureau of the Census monthly postcensal estimates of the civilian noninstitutionalized population of the United
States as of July 1 each year.
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made to hospital outpatient departments. Nearly
85% of all outpatient department visits were made
to a general medicine department. Visits were also
made to surgery and pediatric clinics. Physician
specialty is available for the 5.5 million visits (95%
CI: 3.9–7.1) made to office-based physicians.
General/family practice physicians accounted for
53% or 2.9 million visits. The remainder of visits
were made to internists, pediatricians, neurolo-
gists, otolaryngologists and other specialists.
The CDC reports that the peak of influenza
season can occur anywhere between December
and March (http://www.cdc.gov/flu/about/disease.
htm). The peak months for influenza visits in this
5-year study were February (33.9%), January
(25.2%) and March (12.6%). The observed pattern
of visits reported in the NCHS surveys is consistent
with the CDC’s tracking of the seasonality of
influenza.
Antibiotic prescribing rates and cost (USD,
2003)
During the 5-year period studied, antibiotics were
prescribed during 38% of all ambulatory visits for
influenza. Of the nearly 2.6 million antibiotic
prescriptions (95% CI: 1.3–3.9) recorded during
these encounters, 38.2% were for a broad-spectrum
antibiotic and 61.8% were for a narrow-spectrum
antibiotic (Table 5).
The estimated aggregate cost for the 988 406
(95% CI: 412 473 to 1.6 million) broad-spectrum
antibiotics prescribed was nearly $59 million dollars
(95% CI: $24.5–$93.4 million) (USD, 2003) over the
5-year period, an average of $11.8 million dollars
per year. The estimated cost for the 1.6 million
narrow-spectrum antibiotics prescribed was $33.9
million dollars (95% CI: $15.1–$52.8 million) over
the 5-year period, an average of $6.8 million
dollars per year. The total estimated antibiotic
cost over the 5-year period was $92.9 million
dollars (95% CI: $45.4–$140 million), an average
of $18.6 million dollars per year. Broad-spectrum
antibiotics were prescribed less frequently, but
accounted for 63.5% of the total antibiotic cost
(Table 6).
Total direct medical costs
Over 6.5 million (95% CI: 5.0–8.1) ambulatory care
visits were made in the US by children and adults
age 5–49 years from 1997 to 2001 for a primary
diagnosis of influenza with no secondary diagnoses.
The estimated cost for the physician visits aggre-
gated over the 5-year period was $348 million
dollars (95% CI: $269–$427), an average of $69.6
million dollars per year. The total estimated direct
medical cost including physician payments and
antibiotic costs for the 5-year study period was
$441 million dollars (95% CI: $323 –$560) with
antibiotics contributing more than 20% to the total
direct medical cost (Table 6).
Discussion
This is the first effort to document the extent of
antibiotic use during U.S. ambulatory visits with
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Table 5 Estimated number of antibiotic prescriptions reported at ambulatory care visits by children and adults
age 5–49 years with a sole diagnosis of influenza, 1997–2001.
No. visits % visits Visit rate per 1000n (95% CI)
All Visits 6 575 378 100.0 7.4 (5.6, 9.1)
Antibiotics prescribed at visit
Yes 2 493 781 37.9 2.8 (1.4, 4.1)
No 4 081 597 62.1 4.6 (3.5, 5.6)
No. antibioticsw % antibiotics Visit rate per 1000n (95% CI)
Antibiotic classification
Total antibiotics prescribed 2 590 085 100.0 2.9 (1.4, 4.4)
Broad-spectrum 988 406 38.2 1.1 (0.5, 1.8)
Narrow-spectrum 1 601 679 61.8 1.8 (0.8, 2.8)
Source: CDC’s National Center for Health Statistics. Public Use Files (micro-data), National Ambulatory Health Care Survey and
National Hospital Ambulatory Medical Care Survey, 1997–2001.
nBased on US Bureau of the Census monthly postcensal estimates of the civilian noninstitutionalized population of the United
States as of July 1 each year.
wMore than one antibiotic may have been prescribed at a visit.
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only an influenza diagnosis. Our data show that
over one-third of these visits resulted in an
antibiotic prescription, and that over one-third of
these prescriptions were for a broad-spectrum
agent.
This high rate of antibiotic prescribing for
patients diagnosed only with influenza is troubling
in light of the documented increase in antibiotic
resistance in the US.19–21 Of even greater concern is
the reported reliance on broad-spectrum antibio-
tics since they are more costly and should be
reserved for clinically justified cases. Overuse or
injudicious use of these agents can promote
escalating antimicrobial resistance within both
individual patients and populations.22–26
In order to more fully assess appropriateness, we
examined the survey data for evidence of labora-
tory testing for the pathogen. Surprisingly, there
were too few recorded cases of laboratory tests to
be statistically reliable. This might suggest the
need for ongoing educational efforts aimed at
improving physicians’ clinical diagnostic ap-
proaches when evaluating a patient presenting
with a common viral infection.13 Alternatively, it
might reflect the relative lack of availability of
accurate, reliable and affordable laboratory diag-
nostic methods for the rapid detection of influenza
during the period over which the data were
collected. It has become clear over the past 2
years that rapid diagnostic kits for the purpose of
virologic confirmation of influenza are gaining favor
in many outpatient facilities. Such increased test-
ing, combined with enhanced prevention efforts,
might ultimately result in reductions in inappropri-
ate management of influenza.
To further explore the issue of appropriate
treatment for influenza, we looked at the prescrib-
ing of antiviral drugs such as oseltamivir and
amantadine. We observed that antiviral drugs were
prescribed at 30% of visits; a lower rate than
observed for antibiotics. This may reflect the
relatively late stage of infection that occurs for
many outpatient encounters in which influenza is
diagnosed (at which point antiviral therapy is
clinically ineffective).27
In an effort to identify potentially justifiable
cases of antibiotic prescribing, we examined cases
in which the sole diagnosis was influenza with
pneumonia (ICD-9-CM 487.0). We found too few
cases with this diagnosis to be statistically reliable.
The cases accounted for 1.2% of the visits in which
an antibiotic was prescribed. Ninety-eight percent
of the visits had a sole, primary diagnosis of
influenza with other respiratory manifestations.
Since there is no broad diagnosis code for influenza,
the ICD-9-CM code 487.1 is used to code influenza
with other respiratory manifestations and influenza
not otherwise specified. This is a limitation of the
ICD-9-CM coding system and leads to potential
misclassification bias in this analysis. We recognize
that there may be cases where an antibiotic is
warranted. However, we have attempted to define
the best possible sample by excluding cases with
any secondary diagnoses. Therefore, we conclude
that the vast majority of antibiotic prescriptions
were for uncomplicated cases of influenza.
Due to the small annual number of sample cases,
and the limited span of the study, this study cannot
address the issue of whether or not there is a trend
toward decreased use of antibiotics to treat
influenza.12 Our findings are generally consistent
with a recent report that 28% of managed care
patients diagnosed only with influenza received an
antibiotic.28 Mean outpatient charges for these
patients in 1997–1998 were $171.28 A recent review
of fluroquinolone use in a hospital outpatient
department concluded that 33% of the time there
was no evidence of an infection justifying the use of
an antibiotic, much less a broad-spectrum agent.
The authors concluded that inappropriate use of
antibiotics in the ambulatory setting may be
exacerbating antibiotic resistance.29
While the survey data used for this study do not
capture the entire universe of ambulatory medical
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Table 6 Estimated costs (USD, 2003) of physician visits and antibiotics prescribed for ambulatory care visits by
children and adults age 5–49 years with a sole diagnosis of influenza, 1997–2001.
No. visits Mean Median 5-year sum Average annual cost
Visit cost 6 575 378 $52.95 $51.13 $348 191535 $ 69 638 307
Antibiotic costs 2 493 781 $35.87 $21.17 $ 92 905 499 $ 18 581 100
Broad-spectrum 977 946 $59.69 $59.69 $ 58 997 954 $ 11 799 591
Narrow-spectrum 1 515 835 $21.17 $21.17 $ 33 907 544 $ 6 781 509
Total direct medical cost 6 575 378 $67.08 $60.33 $441 097 033 $ 88 219 407
(visitþ antibiotic costs)
Source: CDC’s National Center for Health Statistics. Public use files (micro-data). National Ambulatory Health Care Survey and
National Hospital Ambulatory Medical Care Survey, 1997–2001.
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care (e.g. community health centers and federal
institutions such as VA outpatient clinics are
excluded) they do permit nationally reliable esti-
mates of care provided in most US mainstream
ambulatory settings. An important limitation of this
study is that diagnoses cannot be specifically
associated with a particular drug, dose, or duration
of therapy, and therefore the appropriateness of an
antibiotic prescription cannot be assessed with
absolute certainty. A further limitation of the data
is that it is not known whether prescriptions were
actually filled or taken as prescribed. Previous
research has shown that up to one-fifth of all new
prescriptions go unfilled.30 Patient compliance
cannot be assumed because patient and pharmacy
records were not audited. However, the data
accurately reflect physicians’ self-reported actions
during patient encounters.
In addition to increasing targeted education of
physicians, both the visit rate for influenza related
care and inappropriate use of antibiotics could be
reduced by higher influenza vaccination rates and
improved diagnostic virology and viral surveillance.
Even among high-risk individuals, such as those age
65 years and older, vaccination rates are lower than
optimal (less than 70%). Less than 20% of 18–49 year
old Americans were ever vaccinated between 1997
and 2002.31
Additional measures that could reduce inap-
propriate care of patients suffering from only a
viral infection is increased laboratory testing of
pathogens and dissemination of local surveillance
data to community-based physicians. A recent
prospective randomized controlled trial of rapid
diagnostic testing of pediatric patients seen in the
emergency room found that once physicians were
aware their patients had influenza, antibiotic use
decreased, prescriptions for antiviral products
increased, and both costs and length of stay were
reduced.32 Two-pronged comprehensive and sys-
tematic efforts aimed at (1) prevention of influen-
za, and (2) accurate diagnostic confirmation of
influenza have the potential to dramatically reduce
antibiotic misuse.
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